Cizzle Biotechnology Holdings plc (“Cizzle”), a UK-based diagnostics company focused on early-stage lung cancer detection, has announced a landmark partnership with Moffitt Cancer Center, Florida’s premier cancer hospital. This collaboration represents a critical advancement in the development of Cizzle’s CIZ1B biomarker assay, which aims to simplify and improve early lung cancer diagnosis using a non-invasive blood test, replacing traditional costly and invasive methods.
Key Highlights:
- Partnership with Moffitt Cancer Center: Moffitt is Florida’s only Comprehensive Cancer Center designated by the US National Cancer Institute, renowned for its cutting-edge lung cancer screening and research programs.
- First clinical evaluation of CIZ1B: This study will concentrate on patients with uncertain lung nodules, assessing how effectively the CIZ1B biomarker can identify lung cancer at an early stage.
- Innovative monoclonal antibodies: Cizzle’s new monoclonal antibodies, developed in collaboration with BBI Solutions, will be utilised in the evaluation process.
- Analysis at the University of York: Blood samples from Moffitt patients will be analysed in the laboratory where the CIZ1B biomarker was first identified.
A Groundbreaking Study
This partnership is included in Moffitt Cancer Center’s Phase 2 research initiative, titled Utilising Biomarkers for Diagnosis, Risk Assessment of Post-Treatment Recurrence, and Long-Term Lung Cancer Survival. The study, led by Dr. Lary Robinson, Director of Moffitt’s Lung Cancer Early Detection Center, will assess the accuracy of Cizzle’s CIZ1B biomarker in early lung cancer detection. The primary goal is to reduce the false positives often associated with CT scans, which can lead to unnecessary and invasive follow-up procedures. By integrating the CIZ1B biomarker into the diagnostic process, the study hopes to streamline and enhance early detection efforts.
Expanding into the US Market
The collaboration with Moffitt Cancer Center marks a significant milestone in Cizzle’s expansion into the US market, driven by its American partner, Cizzle Bio Inc. With a team of highly experienced healthcare professionals and clinicians, Cizzle Bio Inc. is at the forefront of advancing this innovative diagnostic technology in North America. This partnership will play a vital role in demonstrating the clinical value of Cizzle’s blood-based biomarker test in early-stage lung cancer detection across the U.S.
A Global Initiative to Save Lives
Lung cancer remains one of the deadliest forms of cancer, claiming nearly 5,000 lives daily on a global scale. Early detection is crucial in combating the disease, as survival rates significantly increase when lung cancer is identified in its early stages. Cizzle’s CIZ1B biomarker offers a game-changing solution—a cost-effective, non-invasive blood test that could dramatically improve early diagnosis, potentially saving thousands of lives while reducing the financial burden on healthcare systems.
Allan Syms, Executive Chairman of Cizzle Biotechnology, shared his enthusiasm for the collaboration:
Our collaboration with Moffitt Cancer Center marks a significant turning point for Cizzle. Moffitt’s status as one of the most respected cancer centers in the U.S. makes this collaboration a major milestone for advancing our CIZ1B biomarker test. For the first time, patients with suspicious lung nodules will have the opportunity to undergo evaluation using our biomarker as part of their clinical assessment. This collaboration underscores the potential of our test to reduce false positives and better identify at-risk patients for early-stage lung cancer detection. We are thrilled to be working alongside Moffitt to bring this innovation to more patients and improve the standards of lung cancer screening and surveillance.”